Loading...
Loading...
CYAD| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | -31.3M |
| Operating I/L | 18.1M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.1M |
| Pretax | 18.3M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | 18.3M |
Celyad Oncology SA is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. The company's lead product candidates include allogeneic and autologous CAR-T candidates for the treatment of metastatic colorectal cancer, relapsed/refractory multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes. Additionally, Celyad Oncology SA has a preclinical candidate for the treatment of solid tumors. The company generates revenue through the development and potential commercialization of its CAR-T therapies, as well as through licensing agreements and research collaborations with other biopharmaceutical companies.
